Clinical Trial

Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2022-04-14; most recent amendment 2026-04-06.
Trial Details
NCT Number NCT05339256
Lead Sponsor New York State Psychiatric Institute
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Opioid Use Disorder
Enrollment 50 participants
Start Date 2026-06-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13